Video Experimental Relacionado

Updated: Feb 19, 2026

Facile Preparation of 4-Substituted Quinazoline Derivatives

Facile Preparation of 4-Substituted Quinazoline Derivatives

Published on: February 15, 2016

Derivados de Estirilquinolina como Inhibidores de IGF1R

Patryk Zioła¹, Katarzyna Malarz¹, Marcin Pacholczyk²

¹A. Chełkowski Institute of Physics, University of Silesia in Katowice, 75 Pułku Piechoty 1a, 41-500 Chorzów, Poland.

ACS medicinal chemistry letters

|February 18, 2026

Resumen

Los análogos de estirilquinolina muestran efectos antiproliferativos contra el glioblastoma. Estos compuestos son potentes inhibidores de la tirosina quinasa del receptor 1 del factor de crecimiento similar a la insulina, lo que indica un potencial terapéutico.

Área de la Ciencia:

Química Medicinal
Farmacología
Oncología

Sus antecedentes:

El glioblastoma multiforme es un tumor cerebral agresivo con opciones de tratamiento limitadas.
Las vías de señalización de la tirosina quinasa son cruciales en la progresión del glioblastoma.
Los derivados de estirilquinolina han demostrado actividad antiproliferativa.

Objetivo del estudio:

Investigar el potencial inhibidor de la tirosina quinasa de los análogos de estirilquinolina.
Establecer relaciones estructura-actividad para los efectos antiproliferativos contra el glioblastoma.
Identificar dianas específicas de receptores de tirosina quinasa para estos compuestos.

Principales métodos:

Síntesis y cribado de análogos de estirilquinolina para determinar la actividad antiproliferativa.
Análisis de la relación estructura-actividad basado en los efectos de los sustituyentes (OH, NO2, F, OAc).
Cribado contra un panel de receptores de tirosina quinasa y simulaciones de acoplamiento molecular.

Principales resultados:

Los derivados de estirilquinolina exhiben una actividad antiproliferativa significativa contra el glioblastoma.
Los sustituyentes hidroxilo (OH) y nitro (NO2) mejoraron la actividad, mientras que el flúor (F) y el acetato (OAc) la redujeron.
Los compuestos mostraron un alto potencial como inhibidores del receptor 1 del factor de crecimiento similar a la insulina (IGF-1R), respaldado por estudios de acoplamiento molecular.

Conclusiones:

Los derivados de estirilquinolina son candidatos prometedores para el tratamiento del glioblastoma.
La focalización de la vía del receptor 1 del factor de crecimiento similar a la insulina (IGF-1R) con estos análogos ofrece una estrategia terapéutica potencial.
El desarrollo adicional de estos compuestos podría conducir a nuevas terapias para el glioblastoma.

Palabras clave:

inhibidores de IGF1R actividad antiproliferativa glioblastoma multiforme estirilquinolina

Más Videos Relacionados

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Vasodilation of Isolated Vessels and the Isolation of the Extracellular Matrix of Tight-skin Mice

Published on: March 24, 2017

Videos de Conceptos Relacionados

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...